Marketing-authorisation holder · Ireland
Jazz Pharmaceuticals Ireland Limited
23 medicines in 5 countries, as authorisation holder and marketer.
Loading your page…
Loading your page…
Marketing-authorisation holder · Ireland
23 medicines in 5 countries, as authorisation holder and marketer.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
23 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| DEFITELIO80 mg / ml · Solution | Defibrotide | Canada | Marketed | 2017 |
| Enrylaze | Asparaginase | EU (EMA) | Authorised | 2023 |
| ENRYLAZESoluzione iniettabile o per infusione | Asparaginase | Italy | Authorised | |
| Enrylaze 10 mg/0,5 ml oplossing voor injectie/infusieOplossing voor injectie of infusie | Asparaginase | Netherlands | Authorised | 2023 |
| ENRYLAZE 10 MG/0,5 ML, SOLUCION INYECTABLE Y PARA PERFUSION10 mg · Solución inyectable y para perfusión | Asparaginase | Spain | Marketed | 2024 |
| EPIDYOLEXSoluzione orale | Cannabidiol | Italy | Authorised | |
| Epidyolex | Cannabidiol | EU (EMA) | Authorised | 2019 |
| Epidyolex 100 mg/ml, drankDrank | Cannabidiol | Netherlands | Authorised | 2019 |
| EPIDYOLEX 100 MG/ML SOLUCION ORAL100 mg/ml · Solución oral | Cannabidiol | Spain | Marketed | 2019 |
| RYLAZE10 mg / 0.5 ml · Solution | Asparaginase | Canada | Marketed | 2023 |
| VYXEOS100 mg + 44 mg · Powder | Cytarabine, Daunorubicin | Canada | Marketed | 2021 |
| VYXEOS LIPOSOMALPolvere per concentrato per soluzione per infusione | Cytarabine | Italy | Authorised | |
| Vyxeos liposomal 44 mg/100 mg poeder voor concentraat voor oplossing voor infusiePoeder voor concentraat voor oplossing voor infusie | Cytarabine, Daunorubicin | Netherlands | Authorised | 2018 |
| VYXEOS LIPOSOMAL 44 MG/100 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION44 mg + 100 mg · Polvo para concentrado para solución para perfusión | Daunorubicin, Cytarabine | Spain | Marketed | 2018 |
| Vyxeos liposomal (previously Vyxeos) | Daunorubicin, Cytarabine | EU (EMA) | Authorised | 2018 |
| XYREM500 mg / ml · Solution | Sodium oxybate | Canada | Marketed | 2007 |
| XYWAV0.234 g / ml + 0.096 g / ml + 0.13 g / ml + 0.04 g / ml · Solution | Sodium oxybate | Canada | Marketed | 2023 |
| ZEPZELCA4 mg / vial · Powder | Lurbinectedin | Canada | Not marketed | 2021 |
| ZIIHERAPolvere per concentrato per soluzione per infusione | Zanidatamab | Italy | Authorised | |
| Ziihera | Zanidatamab | EU (EMA) | Authorised | 2025 |
| ZIIHERA300 mg / vial · Powder For Solution | Zanidatamab | Canada | Authorised | |
| Ziihera 300 mg poeder voor concentraat voor oplossing voor infusiePoeder voor concentraat voor oplossing voor infusie | Zanidatamab | Netherlands | Authorised | 2025 |
| ZIIHERA 300 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSION300 mg · Polvo para concentrado para solución para perfusión | Zanidatamab | Spain | Authorised | 2026 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 7 | 7 | 0 | CompaniesAll medicines |
| Spain | 4 | 4 | 0 | CompaniesAll medicines |
| European Union (EMA) | 4 | 4 | 0 | CompaniesAll medicines |
| Italy | 4 | 4 | 0 | CompaniesAll medicines |
| Netherlands | 4 | 4 | 0 | CompaniesAll medicines |
Also in the registers of France, United States
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: European Medicines Agency (EPAR data).
Licence: EMA reuse policy (source acknowledgement required)
Fuente de la información: AEMPS (CIMA).
Licence: AEMPS open data reuse with attribution
Source: BDPM (ANSM, HAS, UNCAM).
Licence: Licence Ouverte v1.0
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA presentaciones, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
Fuente de la información: Agencia Española de Medicamentos y Productos Sanitarios www.aemps.gob.es; CIMA medicamentos, acquired 11 October 2026 UTC; each source response/update date retained.
Licence: AEMPS explicit public open-data reuse for citizens and companies; source attribution and update date required
BDPM / ANSM, HAS and UNCAM; original URLs and each update date retained
Licence: BDPM exact Licence Ouverte v1.0 (October 2011)
Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.
Licence: CC BY 4.0; AIFA published open-data catalog
College ter Beoordeling van Geneesmiddelen, Geneesmiddeleninformatiebank metadata, source update 07-10-2026; downloaded 08-10-2026; factual adaptation.
Licence: Conditional noncreative administrative factual metadata; no dataset-wide CC0 claim
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.